Ultra-low PSA target linked to better survival in metastatic prostate cancer

A real-world Veterans Health Administration study of 4,890 men with metastatic hormone-sensitive prostate cancer found that achieving a PSA below 0.2 ng/mL within 9 months of starting testosterone-deprivation therapy was associated with a 54% lower risk of death over a median follow-up of about 2 years. Notably, patients who only achieved a 90% PSA decline without hitting the 0.2 ng/mL threshold did not see a survival benefit. The findings suggest targeting PSA <0.2 ng/mL as a key treatment-success metric and indicate that more aggressive therapy may be warranted for those who do not reach this level; adding another drug to further block testosterone improved odds of reaching the threshold.